JP Patent

JP7030813B2 — 前立腺癌の処置のためのシロリムスの腫瘍内投与

Assigned to Santen Pharmaceutical Co Ltd · Expires 2022-03-07 · 4y expired

What this patent protects

Patent listed against Risperdal.

Drugs covered by this patent

Risperdal (risperidone) · Johnson & Johnson (Janssen)

Patent Metadata

Patent number: JP7030813B2
Jurisdiction: JP
Classification: —
Expires: 2022-03-07
Drug substance claim: No
Drug product claim: No
Assignee: Santen Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.